Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report) saw unusually large options trading on Monday. Stock investors acquired 2,704 call options on the stock. This is an increase of 122% compared to the average volume of 1,216 call options.
Microbot Medical Stock Down 16.5%
MBOT traded down $0.47 during trading hours on Monday, reaching $2.35. 3,871,718 shares of the company's stock traded hands, compared to its average volume of 1,709,578. The firm has a 50-day moving average price of $2.36 and a 200 day moving average price of $1.82. The firm has a market capitalization of $85.31 million, a PE ratio of -2.92 and a beta of 1.14. Microbot Medical has a 52-week low of $0.82 and a 52-week high of $3.38.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last released its quarterly earnings data on Wednesday, May 21st. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.07. Equities analysts predict that Microbot Medical will post -0.71 EPS for the current fiscal year.
Hedge Funds Weigh In On Microbot Medical
A number of hedge funds and other institutional investors have recently made changes to their positions in MBOT. Geode Capital Management LLC lifted its stake in Microbot Medical by 7.9% in the fourth quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company's stock worth $160,000 after acquiring an additional 10,442 shares during the period. Renaissance Technologies LLC purchased a new position in Microbot Medical during the fourth quarter valued at approximately $118,000. Virtu Financial LLC purchased a new stake in Microbot Medical during the first quarter worth $42,000. Finally, Goldman Sachs Group Inc. bought a new stake in Microbot Medical during the 1st quarter valued at $57,000. Institutional investors own 16.30% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a "buy" rating and set a $9.00 price objective on shares of Microbot Medical in a research report on Thursday, April 10th.
Check Out Our Latest Analysis on Microbot Medical
Microbot Medical Company Profile
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.